Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
236M
-
Number of holders
-
75
-
Total 13F shares, excl. options
-
50.2M
-
Shares change
-
-1.63M
-
Total reported value, excl. options
-
$46M
-
Value change
-
-$1.39M
-
Put/Call ratio
-
0.43
-
Number of buys
-
29
-
Number of sells
-
-27
-
Price
-
$0.92
Significant Holders of Akebia Therapeutics, Inc. - Common Stock (AKBA) as of Q2 2023
89 filings reported holding AKBA - Akebia Therapeutics, Inc. - Common Stock as of Q2 2023.
Akebia Therapeutics, Inc. - Common Stock (AKBA) has 75 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 50.2M shares
of 236M outstanding shares and own 21.27% of the company stock.
Largest 10 shareholders include Alerce Investment Management, L.P. (16.2M shares), VANGUARD GROUP INC (7.81M shares), ACADIAN ASSET MANAGEMENT LLC (7.46M shares), RENAISSANCE TECHNOLOGIES LLC (3.33M shares), BlackRock Inc. (2.74M shares), MILLENNIUM MANAGEMENT LLC (2.01M shares), GEODE CAPITAL MANAGEMENT, LLC (1.77M shares), JACOBS LEVY EQUITY MANAGEMENT, INC (1.35M shares), FEDERATED HERMES, INC. (965K shares), and VICTORY CAPITAL MANAGEMENT INC (662K shares).
This table shows the top 75 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.